Compound reference
KPV is investigated for inflammatory signaling in intestinal and immune cells. Its potential application concerns intestinal inflammation and barrier biology, with the cited evidence remaining preclinical.
Explore the selected studies, their findings and their limits.
A study in intestinal and immune-cell cultures found reduced inflammatory signaling after KPV uptake through the PepT1 transporter. In two mouse models of chemically induced colitis, researchers also reported lower inflammatory measures. This supports investigation of intestinal inflammation pathways, but does not establish treatment of inflammatory bowel disease in people or digestive illness in dogs.
The studies discussed here do not establish the safety or effectiveness of this catalog formula in dogs. Rat, mouse, cell-culture and human findings are not canine clinical results; they also do not establish absorption or effects from the listed oral formula.
For more information, contact info@aurevixpeptides.com.
Editorial review: September 23, 2026
